Skip to content
Search
Close this search box.
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • CONTACT
Menu
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • CONTACT
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Investors
  • Our Solution
    • CSF-1 Overview
    • About Presbyopia
    • Mechanism of Action
  • News & Events
  • Contact Us

    • Orasis Pharmaceuticals Closes $13 Million Series B Financing

    • Post author:foothold
    • Post published:June 5, 2018
    • Post category:Press Releases

    HERZLIYA, Israel, June 5, 2018 – Orasis Pharmaceuticals LTD., a privately-held, clinical-stage pharmaceutical company focused on developing an innovative eye drop for the treatment of presbyopia symptoms, today announced the…

    Continue ReadingOrasis Pharmaceuticals Closes $13 Million Series B Financing

    Recent Posts

    • FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia 
    • Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
    • Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
    • Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
    • Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

    Recent Comments

      Archives

      • February 2023
      • January 2023
      • April 2022
      • March 2022
      • October 2021
      • April 2021
      • October 2020
      • September 2020
      • October 2019
      • March 2019
      • December 2018
      • November 2018
      • October 2018
      • June 2018

      Categories

      • Press Releases
      • Events

      Meta

      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org

      HOME

      ABOUT US

      • Company Overview
      • Leadership Team
      • Board of Directors
      • Investors
      • Company Overview
      • Leadership Team
      • Board of Directors
      • Investors

      OUR SOLUTION

      • CSF-1 Overview
      • About Presbyopia
      • Mechanism of Action
      • CSF-1 Overview
      • About Presbyopia
      • Mechanism of Action

      NEWS & EVENTS

      CONTACT

      info@orasis-pharma.com
      Linkedin-in Twitter